Practical strategies for turning tutorials into active, inclusive learning spaces, from designing hands-on activities and valuing student contributions to building rapport and providing effective ...

Amgen is entering a pivotal period the as it moves beyond its Enbrel franchise and repositions around obesity, rare disease and next-generation oncology. While Enbrel has entered a period of decline ...

DENVER — Colorado's first-in-the-nation law that allows a state board to limit prescription drug prices is facing a new legal challenge. The pharmaceutical company Amgen is suing the Colorado ...

Add Yahoo as a preferred source to see more of our stories on Google. Sen. Julie Gonzales speaks at the Colorado Capitol on Oct. 7, 2025. Colorado's Prescription Drug Affordability Board voted to set ...

Colorado regulators have approved a dramatic price cap on one of the nation’s best-selling drugs, cutting its price to less than one-third of its previous level, in a novel attempt by a state to ...

Colorado makes history as first state to cap prescription drug prices, targeting Enbrel, used for several autoimmune conditions. Trump pulls US out of more than 30 UN bodies Lack of oil aboard ...

Doctors prescribe Enbrel for arthritis, psoriasis, and other conditions. The medication can cause side effects that are mild and some serious ones. Serious side effects of Enbrel include neurologic ...

Amgen reported 9% revenue growth and 21% non-GAAP EPS growth in the second quarter. Management raised its 2025 revenue guidance by $500 million at the midpoint to $35 billion-$36 billion and increased ...

There are currently six states with active Prescription Drug Affordability Boards (PDABs) — Colorado, Maryland, Washington, Oregon, New Hampshire, and Minnesota. As PDABs march toward declaring the ...

Alston & Bird represent plaintiff Sandoz Inc. in an antitrust lawsuit against Amgen. Munger, Tolles & Olson and Kaufman & Canoles represent Amgen in a related case in the Eastern District of Virginia.

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the United States. And unless a court rules otherwise, the Southern California ...